Skip to main content

Naloxone

Take Home Naloxone in the UK

Naloxone (provided under the brand names Prenoxad and Nyxoid in the UK) is a medication used to reverse opioid overdose. Since 2015, this medication has been more widely available in the UK as a ‘take home’ emergency medication.

NALOXONE.ORG.UK

This website aims to be a hub for information, guidance, news and research on Take Home Naloxone (THN). The main focus is on THN in the UK, although we have included select pieces of information on the supply of naloxone internationally.

PHE Guidance

Updated 18 February 2019
Public Health England have released updated guidance on take home naloxone in the UK, entiled ‘Widening the Availability of Naloxone’. This can be found on the PHE website.
  • Drug services can supply naloxone without a prescription
  • Products that drug services can supply
  • Responsibility for deciding who can supply naloxone
  • People who can be supplied naloxone by a drug service
  • Using naloxone to save a person’s life without their permission
  • Clinical governance in drug treatment services
  • Guidance for hostels, homeless shelters and housing associations
  • Side effects associated with naloxone

Cost-effectiveness analysis of alternative naloxone distribution strategies: First responder and lay distribution in the United States

Written on . Posted in .

The U.S. is facing an unprecedented number of opioid-related overdose deaths, and an array of other countries have experienced increases in opioid-related fatalities. In the U.S., naloxone is increasingly distributed to first responders to improve early administration to overdose victims, but its cost-effectiveness has not been studied. Lay distribution, in contrast, has been found to be cost-effective, but rising naloxone prices and increased mortality due to synthetic opioids may reduce cost-effectiveness. We evaluate the cost-effectiveness of increased naloxone distribution to (a) people likely to witness or experience overdose (“laypeople”); (b) police and firefighters; (c) emergency medical services (EMS) personnel; and (d) combinations of these groups.

This year the Scottish Drugs Forum  #StopTheDeaths campaign highlights the role we all have in recognising and intervening when a person overdoses.

Overdose is not a rare occurrence and the difference between an overdose and a fatal overdose depends upon the immediate actions of people present at the time. You could save a life by recognising an overdose.  

#StopTheDeaths images © SDF 2021

News/Updates

Pride and Prejudice

Written on . Posted in .

As Overdose Awareness Day approached, the millionth kit of injectable naloxone was distributed. Drink Drug News magazine looks back at the story of this lifesaving intervention.

Nonprescription Naloxone Available For Retail Sales (USA)

Written on . Posted in , .

This nonprescription availability is an important milestone for states and territories, community organizations, harm reduction advocates, those working to prevent overdose, and people at risk for overdose. State policy has evolved since the initial FDA approval of naloxone in 1971 to reduce access barriers and allow distribution to laypersons for emergency response. More than 20 years ago, harm reduction organizations spearheaded efforts to distribute naloxone to laypersons, particularly people who use drugs and their friends and families. Significant research has demonstrated naloxone is safe and effective for layperson use even with brief training.

Make naloxone routinely available to police, paramedics and public, says Turning Point

Written on . Posted in .

Turning Point is calling on the government to make naloxone routinely available to the police, paramedics and the general public, as only treatment and healthcare staff are currently able to distribute the drug.